Antagonists of HMG1 for treating inflammatory conditions
AssigneeThe Feinstein Institute for Medical Research
InventorsKevin J. Tracey, Haichao Wang
Life of this patent
Estimating the term…
Abstract
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
Claims22
An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody inhibits HMG1-mediated activation of the inflammatory cytokine cascade and is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a single chain antibody, a human antibody and a humanized antibody.
An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a monoclonal antibody that inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a chimeric antibody that inhibits HMG 1-mediated activation of the inflammatory cytokine cascade.
An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a single chain antibody that inhibits HMG 1-mediated activation of the inflammatory cytokine cascade.
An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a human antibody that inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
An isolated antibody that specifically binds to an HMG1 protein or an antigenic fragment thereof, wherein said antibody is a humanized antibody that inhibits HMG 1-mediated activation of the inflammatory cytokine cascade.
Dependencies are inferred from the claim text.